Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers

Brain

Volumn 139, Issue 5, 2016, Pages 1568-1586

  Umeda, Tomohiro ^a,b   Ono, Kenjiro ^c   Sakai, Ayumi ^a   Yamashita, Minato ^a   Mizuguchi, Mineyuki ^d   Klein, William L ^e   Yamada, Masahito ^c   Mori, Hiroshi ^a,b   Tomiyama, Takami ^a,b  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOYAMA   (Japan)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

autophagy; mitochondria; neurodegenerative disease; oligomer; prevention

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CURCUMIN; CYTOCHROME C; EPIGALLOCATECHIN GALLATE; INOSITOL; MYRICETIN; RIFAMPICIN; TAU PROTEIN; CASPASE 3; MICROTUBULE ASSOCIATED PROTEIN; NEUROPROTECTIVE AGENT; SEQUESTOSOME 1; SYNUCLEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL LOSS; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; MALE; MICROGLIA; MITOCHONDRION; MOUSE; NONHUMAN; OLIGOMERIZATION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; SYNAPSE; TAUOPATHY; ANIMAL; CELL CULTURE; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; FEMALE; HIPPOCAMPUS; MAZE TEST; MEMORY DISORDERS; METABOLISM; PHOSPHORYLATION; TAUOPATHIES; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CASPASE 3; CELLS, CULTURED; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIPPOCAMPUS; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; MICROGLIA; MICROTUBULE-ASSOCIATED PROTEINS; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; RIFAMPIN; SEQUESTOSOME-1 PROTEIN; SYNAPSES; SYNUCLEINS; TAU PROTEINS; TAUOPATHIES;

EID: 84966639564     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww042     Document Type: Article

References (71)

1. Balali-Mood K, Ashley RH, Hauss T, Bradshaw JP. Neutron diffraction reveals sequence-specific membrane insertion of pre-fibrillar islet amyloid polypeptide and inhibition by rifampicin. FEBS Lett 2005; 579: 1143-8.
2. Bastianetto S, Yao ZX, Papadopoulos V, Quirion R. Neuroprotective effects of green and black teas and their catechin gallate esters against b-amyloid-induced toxicity. Eur J Neurosci 2006; 23: 55-64.
3. Bi W, Zhu L, Jing X, Tao E. Rifampicin and Parkinson's disease. Neurol Sci 2013; 34: 137-41.
4. Castillo-Carranza DL, Guerrero-Muñ oz MJ, Sengupta U, Hernandez C, Barrett AD, Dineley K, et al. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model. J Neurosci 2015; 35: 4857-68.
5. Chen J, Raymond K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob 2006; 5: 3
6. Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, et al. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 2007; 282: 23818-28.
7. Chui DH, Tabira T, Izumi S, Koya G, Ogata J. Decreased b-amyloid and increased abnormal Tau deposition in the brain of aged patients with leprosy. Am J Pathol 1994; 145: 771-5.
8. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-b protein specifically disrupt cognitive function. Nat Neurosci 2005; 8: 79-84.
9. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerlaet FM. Synergistic Interactions between amyloid-b, tau, and--synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010; 30: 7281-9.
10. Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, Marinec PS, et al. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 2012; 8: 609-22.
11. Danzer KM, Krebs SK, Wolff M, Birk G, Hengerer B. Seeding induced by--synuclein oligomers provides evidence for spreading of--synuclein pathology. J Neurochem 2009; 111: 192-203.
12. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, et al. amyloid-b oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 2007; 282: 11590-601.
13. De Moura MB, Dos Santos LS, Van Houten B. Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen 2010; 51: 391-405.
14. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 2005; 280: 17294-300.
15. Diógenes MJ, Dias RB, Rombo DM, Vicente Miranda H, Maiolino F, Guerreiro P, et al Extracellular--synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci 2012 32 11750-62.
16. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. Arch Neurol 2001; 58: 186-90.
17. Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehrpour M, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol 2014; 112: 24-49.
18. Hamaguchi T, Ono K, Murase A, Yamada M. Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-b aggregation pathway. Am J Pathol 2009; 175: 2557-65.
19. Harroun TA, Bradshaw JP, Ashley RH. Inhibitors can arrest the membrane activity of human islet amyloid polypeptide independently of amyloid formation. FEBS Lett 2001; 507: 200-4.
20. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274: 99-102.
21. Imbimbo BP, Giardina GA.--Secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr Top Med Chem 2011; 11: 1555-70.
22. Komatsu M, Ichimura Y. Physiological significance of selective degradation of p62 by autophagy. FEBS Lett 2010; 584: 1374-8.
23. Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, et al. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular amyloid-b and differential drug responsiveness. Cell Stem Cell 2013; 12: 487-96.
24. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from amyloid-b1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448-53.
25. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, et al. Monoclonal antibodies that target pathological assemblies of amyloid-b. J Neurochem 2007; 100: 23-35.
26. Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC. Juckeret M. Soluble amyloid-b seeds are potent inducers of cerebral b-amyloid deposition. J Neurosci 2011; 31: 14488-95.
27. Larson ME, Sherman MA, Greimel S, Kuskowski M, Schneider JA, Bennett DA, et al. Soluble--synuclein is a novel modulator of Alzheimer's disease pathophysiology. J Neurosci 2012; 32: 10253-66.
28. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, et al. Alzheimer brainderived tau oligomers propagate pathology from endogenous tau. Sci Rep 2012; 2: 700
29. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001; 24: 1121-59.
30. Li J, Zhu M, Rajamani S, Uversky VN, Fink AL. Rifampicin inhibits--synuclein fibrillation and disaggregates fibrils. Chem Biol 2004; 11: 1513-21.
31. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001; 21: 8370-7.
32. Low PA, Robertson D, Gilman S, Kaufmann H, Singer W, Biaggioni I, et al. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014; 13: 268-75.
33. Mancuso M, Coppede F, Migliore L, Siciliano G, Murri L. Mitochondrial dysfunction, oxidative stress and neurodegeneration. J Alzheimers Dis 2006; 10: 59-73.
34. Martin ZS, Neugebauer V, Dineley KT, Kayed R, Zhang W, Reese LC, et al.--Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. J Neurochem 2012; 120: 440-52.
35. McGeer PL, Harada N, Kimura H, McGeer EG, Schulzer M. Prevalence of dementia amongst elderly Japanese with leprosy: apparent effect of chronic drug therapy. Dementia 1992; 3: 146-9.
36. McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid b peptide and inhibit amyloid-b-induced toxicity. J Biol Chem 2000; 275: 18495-502.
37. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, et al. Cyclohexanehexol inhibitors of amyloid-b aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 2006; 12: 801-8.
38. Molloy DW, Standish TI, Zhou Q, Guyatt G, DARAD Study Group. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial. Int J Geriatr Psychiatry 2013; 28: 463-70.
39. Namba Y, Kawatsu K, Izumi S, Ueki A, Ikeda K. Neurofibrillary tangles and senile plaques in brain of elderly leprosy patients. Lancet 1992; 340: 978
40. Nishitsuji K, Tomiyama T, Ishibashi K, Ito K, Teraoka R, Lambert MP, et al. The E693-mutation in amyloid precursor protein increases intracellular accumulation of amyloid b oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. Am J Pathol 2009; 174: 957-69.
41. No authors. Rifampin. Tuberculosis (Edinb) 2008; 8: 151-4.
42. Nomura S, Umeda T, Tomiyama T, Mori H. The E693-(Osaka) mutation in amyloid precursor protein potentiates cholesterolmediated intracellular amyloid b toxicity via its impaired cholesterol efflux. J Neurosci Res 2013; 91: 1541-50.
43. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 2003; 87: 172-81.
44. Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent antiamyloidogenic effects for Alzheimer's b-amyloid fibrils in vitro. J Neurosci Res 2004; 75: 742-50.
45. Ono K, Condron MM, Teplow DB. Structure-neurotoxicity relationships of amyloid b-protein oligomers. Proc Natl Acad Sci USA 2009; 106: 14745-50.
46. Ono K, Li L, Takamura Y, Yoshiike Y, Zhu L, Han F, et al. Phenolic compounds prevent amyloid b-protein oligomerization and synaptic dysfunction by site-specific binding. J Biol Chem 2012; 287: 14631-43.
47. Ozcelik S, Fraser G, Castets P, Schaeffer V, Skachokova Z, Breu K, et al. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS One 2013; 8: e62459
48. Panza F, Logroscino G, Imbimbo BP, Solfrizzi V. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease Curr Opin Psychiatry 2014; 27: 128-37.
49. Qosa H, Abuznait AH, Hill RA, Kaddoumi A. Enhanced brain amyloid-b clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J Alzheimers Dis 2012; 31: 151-65.
50. Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, et al. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci USA 2005; 102: 10427-32.
51. Rezai-Zadeh K, Arendash GW, Hou H, Fernandez F, Jensen M, Runfeldt M, et al. Green tea epigallocatechin-3-gallate (EGCG) reduces b-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res 2008; 1214: 177-87.
52. Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M. Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain 2012; 135: 2169-77.
53. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-42.
54. Shimada K, Motoi Y, Ishiguro K, Kambe T, Matsumoto SE, Itaya M, et al. Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion. Neurobiol Dis 2012; 46: 101-8.
55. Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med 2011; 3: 111cm33
56. Takahashi R, Ono K, Takamura Y, Mizuguchi M, Ikeda T, Nishijo H, et al. Phenolic compounds prevent the oligomerization of--synuclein and reduce synaptic toxicity. J Neurochem 2015; 134: 943-55.
57. Tomiyama T, Asano S, Suwa Y, Morita T, Kataoka K, Mori H, et al. Rifampicin prevents the aggregation and neurotoxicity of amyloid b protein in vitro. Biochem Biophys Res Commun 1994; 204: 76-83.
58. Tomiyama T, Shoji A, Kataoka K, Suwa Y, Asano S, Kaneko H, et al. Inhibition of amyloid b protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J Biol Chem 1996; 271: 6839-44.
59. Tomiyama T, Kaneko H, Kataoka K, Asano S, Endo N. Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Biochem J 1997; 322: 859-65.
60. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, et al. A new amyloid b variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 2008; 63: 377-87.
61. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, et al. A mouse model of amyloid b oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 2010; 30: 4845-56.
62. Ubhi K, Rockenstein E, Mante M, Patrick C, Adame A, Thukral M, et al. Rifampicin reduces--synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport 2008; 19: 1271-6.
63. Umeda T, Tomiyama T, Sakama N, Tanaka S, Lambert MP, Klein WL, et al. Intraneuronal amyloid b oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res 2011; 89: 1031-42.
64. Umeda T, Yamashita T, Kimura T, Ohnishi K, Takuma H, Ozeki T, et al. Neurodegenerative disorder FTDP-17-related tau intron 10 + 16C ! T mutation increases tau exon 10 splicing and causes tauopathy in transgenic mice. Am J Pathol 2013; 183: 211-25.
65. Umeda T, Maekawa S, Kimura K, Takashima A, Tomiyama T, Mori H. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice. Acta Neuropathol 2014; 127: 685-98.
66. Umeda T, Eguchi H, Kunori Y, Matsumoto Y, Taniguchi T, Mori H, et al. Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice. Ann Clin Transl Neurol 2015; 2: 241-55.
67. Vidal RL, Matus S, Bargsted L, Hetz C. Targeting autophagy in neurodegenerative diseases. Trends Pharmacol Sci 2014; 35: 583-91.
68. von Bergen M, Barghorn S, Biernat J, Mandelkow EM, Mandelkow E. Tau aggregation is driven by a transition from random coil to beta sheet structure. Biochim Biophys Acta 2005; 1739: 158-66.
69. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-9.
70. Xu J, Wei C, Xu C, Bennett MC, Zhang G, Li F, et al. Rifampicin protects PC12 cells against MPP +-induced apoptosis and inhibits the expression of an--Synuclein multimer. Brain Res 2007; 1139: 220-5.
71. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid b oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005; 280: 5892-901.